Amedeo Smart

Free Medical Literature Service

 

Amedeo

Chronic Heart Failure
  Free Subscription

Articles published in
Circulation
    August 2025
  1. SOHNS C, Moersdorf M, Marrouche NF, Costard-Jaeckle A, et al
    3-Year Outcomes of Catheter Ablation in Patients with End-Stage Heart Failure and Atrial Fibrillation.
    Circulation. 2025 Aug 31. doi: 10.1161/CIRCULATIONAHA.125.075787.
    >> Share

  2. BERG DD, Patel SM, Haller PM, Cange AL, et al
    Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.
    Circulation. 2025 Aug 29. doi: 10.1161/CIRCULATIONAHA.125.076575.
    >> Share

  3. KORNELIUS E
    Letter by Kornelius Regarding Article, "Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial".
    Circulation. 2025;152:e64.
    >> Share

  4. DOCHERTY KF, Henderson AD, Jhund PS, Solomon SD, et al
    Response by Docherty et al to Letter Regarding Article, "Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial".
    Circulation. 2025;152:e65-e66.
    >> Share

  5. XIONG J, Zhang S, Geng Z, Lin J, et al
    An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure.
    Circulation. 2025 Aug 18. doi: 10.1161/CIRCULATIONAHA.125.074845.
    >> Share

  6. KORNELIUS E
    Letter by Kornelius Regarding Article, "Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure".
    Circulation. 2025;152:e63.
    >> Share

  7. JHA AK
    Letter by Jha Regarding Article, "Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial".
    Circulation. 2025;152:e48-e49.
    >> Share

    July 2025
  8. PERGOLA V, Trancuccio A, Kukavica D, Mazzanti A, et al
    Genotype-Specific Outcomes of Desmosomal Cardiomyopathies.
    Circulation. 2025;152:233-245.
    >> Share

  9. WANG Q, Ismahil MA, Zhu Y, Rokosh G, et al
    CD206(+)IL-4Ralpha(+) Macrophages Are Drivers of Adverse Cardiac Remodeling in Ischemic Cardiomyopathy.
    Circulation. 2025;152:257-273.
    >> Share

  10. SCHUMACHER KR, Rosenthal DN, Batazzi A, Yu S, et al
    The Impact of Fontan Circulatory Failure on Heart Transplant Survival: A 20-Center Retrospective Cohort Study.
    Circulation. 2025 Jul 9. doi: 10.1161/CIRCULATIONAHA.124.072961.
    >> Share

    June 2025
  11. GUO X, Huang C, Zhang L, Hu G, et al
    Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF.
    Circulation. 2025;151:1651-1666.
    >> Share

  12. PANDEY A, Thomas T, Ji Y, Kroger B, et al
    TET2-Mutant Clonal Hematopoiesis Promotes Heart Failure With Preserved Ejection Fraction.
    Circulation. 2025;151:1622-1625.
    >> Share

  13. FONSEKA O, Raja R, Ross C, Gare SR, et al
    XBP1s-EDEM2 Prevents the Onset and Development of HFpEF by Ameliorating Cardiac Lipotoxicity.
    Circulation. 2025;151:1583-1605.
    >> Share

    May 2025
  14. ZHENG Y, Cao Y, Wang W, Tong Y, et al
    Dusp14-Mediated Dephosphorylation of MLKL Protects Against Cardiomyocyte Necroptosis in Hypothyroidism-Induced Heart Failure.
    Circulation. 2025 May 13. doi: 10.1161/CIRCULATIONAHA.125.074353.
    >> Share

  15. METRA M, Tomasoni D, Adamo M, Anker SD, et al
    Evidence Generation and Implementation of Transcatheter Interventions for Atrioventricular Valvular Heart Disease in Heart Failure: Current Status and Future Directions.
    Circulation. 2025;151:1342-1363.
    >> Share

  16. MICHEL LYM, Esfahani H, De Mulder D, Verdoy R, et al
    An NRF2/beta3-Adrenoreceptor Axis Drives a Sustained Antioxidant and Metabolic Rewiring Through the Pentose-Phosphate Pathway to Alleviate Cardiac Stress.
    Circulation. 2025;151:1312-1328.
    >> Share

    April 2025
  17. NAKAMORI S, Omori T, Fujimoto N, Ishida M, et al
    Interplay Between Epicardial Adipose Tissue and Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2025;151:1294-1296.
    >> Share

  18. KHAN SS, Breathett K, Braun LT, Chow SL, et al
    Risk-Based Primary Prevention of Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2025 Apr 16. doi: 10.1161/CIR.0000000000001307.
    >> Share

  19. BUTLER J, Usman MS, Gandotra C, Salman A, et al
    Patient-Reported Outcomes as End Points in Heart Failure Trials.
    Circulation. 2025;151:1111-1125.
    >> Share

  20. OMLAND T, Mills NL
    Natriuretic Peptides for the Diagnosis of Heart Failure With Preserved Ejection Fraction.
    Circulation. 2025;151:990-992.
    >> Share

  21. GLARGAARD S, Hartvig Thomsen J, Tuxen C, Lindholm MG, et al
    A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.
    Circulation. 2025 Apr 1. doi: 10.1161/CIRCULATIONAHA.124.073521.
    >> Share

    March 2025
  22. EBERLY L, Tennison A, Morgan L, Smith M, et al
    Centering Dine (Navajo) Voices: Barriers, Facilitators, and Perceptions of Cardiac Care among Patients with Heart Failure in Rural Navajo Nation.
    Circulation. 2025 Mar 31. doi: 10.1161/CIRCULATIONAHA.124.073166.
    >> Share

  23. KAR S, Makkar RR, Whisenant BK, Hamid N, et al
    Two-year Outcomes of Transcatheter Edge-to-edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Trial.
    Circulation. 2025 Mar 30. doi: 10.1161/CIRCULATIONAHA.125.074536.
    >> Share

  24. CHEN L, Hu Y, Saguner AM, Bauce B, et al
    Natural History and Clinical Outcomes of Patients With DSG2/DSC2 Variant-Related Arrhythmogenic Right Ventricular Cardiomyopathy.
    Circulation. 2025 Mar 24. doi: 10.1161/CIRCULATIONAHA.124.072226.
    >> Share

  25. HOEPER MM, Oerke B, Wissmuller M, Leuchte H, et al
    Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.
    Circulation. 2025;151:e763.
    >> Share

  26. BASILE C, Lindberg F, Benson L, Guidetti F, et al
    Withdrawal of Guideline-Directed Medical Therapy in Patients With Heart Failure and Improved Ejection Fraction.
    Circulation. 2025 Mar 17. doi: 10.1161/CIRCULATIONAHA.124.072855.
    >> Share

  27. FILIPP M, Ge ZD, DeBerge M, Lantz C, et al
    Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction.
    Circulation. 2025 Mar 12. doi: 10.1161/CIRCULATIONAHA.124.070248.
    >> Share

  28. DAI H, Lu X, Zhou X
    Letter by Dai et al Regarding Article, "Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction".
    Circulation. 2025;151:e686.
    >> Share

  29. YANCY CW
    Heart Failure: A Century View, From Failure to Function.
    Circulation. 2025;151:585-588.
    >> Share

    February 2025
  30. LIU X, Wang Q, Li X, Yang Y, et al
    Fast Degradation of MecciRNAs by SUPV3L1/ELAC2 Provides a Novel Opportunity to Tackle Heart Failure With Exogenous MecciRNA.
    Circulation. 2025 Feb 20. doi: 10.1161/CIRCULATIONAHA.124.070840.
    >> Share

  31. BRAUMANN S, Macherey-Meyer S, Polzin A, Costard-Jackle A, et al
    MYSTERY-HF - Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction - a Phase II Randomized Controlled Trial.
    Circulation. 2025 Feb 12. doi: 10.1161/CIRCULATIONAHA.125.074085.
    >> Share

  32. SHEN L, Jhund PS, McMurray JJV
    Response by Shen et al to Letter Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF".
    Circulation. 2025;151:e38.
    >> Share

  33. TUNCEZ A, Gurses KM
    Letter by Tuncez and Gurses Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF".
    Circulation. 2025;151:e37.
    >> Share

    January 2025
  34. KUEHN BM
    Kidney Decline Predicts Worse Heart Failure Outcomes.
    Circulation. 2025;151:348-350.
    >> Share

  35. REDDY YNV, Tada A, Obokata M, Carter RE, et al
    Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting.
    Circulation. 2025 Jan 22. doi: 10.1161/CIRCULATIONAHA.124.072156.
    >> Share

  36. PARK SJ, Kang DH
    Response by Park and Kang to Letter Regarding Article, "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial".
    Circulation. 2025;151:e28.
    >> Share

  37. MORDI IR, McCrimmon RJ, Lang CC
    SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap.
    Circulation. 2025;151:199-201.
    >> Share

  38. WANG J, Peng Y
    Letter by Wang and Peng Regarding Article, "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial".
    Circulation. 2025;151:e27.
    >> Share

  39. DERKS W, Rode J, Collin S, Rost F, et al
    A Latent Cardiomyocyte Regeneration Potential in Human Heart Disease.
    Circulation. 2025;151:245-256.
    >> Share

    December 2024
  40. YAMADA Y, Sadahiro T, Nakano K, Honda S, et al
    Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 Dec 14. doi: 10.1161/CIRCULATIONAHA.123.067504.
    >> Share

  41. DOI SN, Butt JH, Thune JJ, Nielsen JC, et al
    Left Ventricular Ejection Fraction and Implantable Cardioverter-Defibrillator in Non-ischemic Heart Failure with Reduced Ejection Fraction: Insights from DANISH.
    Circulation. 2024 Dec 10. doi: 10.1161/CIRCULATIONAHA.124.071777.
    >> Share

  42. ALVAREZ-GARCIA J
    Cognitive Dysfunction in Heart Failure With Preserved Ejection Fraction: Uncovering the Consequences of an Overlooked Comorbidity.
    Circulation. 2024;150:1928-1930.
    >> Share

  43. YANG X, Zhang Z
    Letter by Yang and Zhang Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial".
    Circulation. 2024;150:e468.
    >> Share

  44. SANDHU AT, Spertus JA, Heidenreich PA
    Reply by Sandhu et al to Letter Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial".
    Circulation. 2024;150:e469-e470.
    >> Share

    November 2024
  45. KEHR D, Ritterhoff J, Glaser M, Jarosch L, et al
    S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models.
    Circulation. 2024 Nov 21. doi: 10.1161/CIRCULATIONAHA.123.066961.
    >> Share

  46. JI Y, Zhang MJ, Wang W, Norby FL, et al
    Association of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS.
    Circulation. 2024 Nov 21. doi: 10.1161/CIRCULATIONAHA.124.070278.
    >> Share

  47. ZILE MR, Borlaug BA, Kramer CM, Baum SJ, et al
    Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity.
    Circulation. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072679.
    >> Share

  48. VOORRIPS SN, Westenbrink BD
    Ketone Treatment in Heart Failure With Preserved Ejection Fraction: Recharging the Heart or Reducing Filling Pressures?
    Circulation. 2024;150:1584-1587.
    >> Share

    October 2024
  49. SHEN L, Dewan P, Ferreira JP, Cunningham JW, et al
    Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
    Circulation. 2024 Oct 21. doi: 10.1161/CIRCULATIONAHA.124.070553.
    >> Share

  50. SOHNS C, Sommer P
    Patients With Advanced Heart Failure and Atrial Fibrillation Deserve an Attempt at Catheter Ablation as First-Line Therapy.
    Circulation. 2024;150:1220-1222.
    >> Share

  51. BEDIOUNE I, Gandon-Renard M, Dessillons M, Barthou A, et al
    Essential Role of the RIalpha Subunit of cAMP-Dependent Protein Kinase in Regulating Cardiac Contractility and Heart Failure Development.
    Circulation. 2024 Oct 2. doi: 10.1161/CIRCULATIONAHA.124.068858.
    >> Share

  52. JIA K, Cheng H, Ma W, Zhuang L, et al
    RNA Helicase DDX5 Maintains Cardiac Function by Regulating CamkIIdelta Alternative Splicing.
    Circulation. 2024;150:1121-1139.
    >> Share

  53. KNEUER JM, Grajek IA, Winkler M, Erbe S, et al
    Novel Long Noncoding RNA HEAT4 Affects Monocyte Subtypes, Reducing Inflammation and Promoting Vascular Healing.
    Circulation. 2024;150:1101-1120.
    >> Share

    September 2024
  54. DOCHERTY KF, Henderson AD, Jhund PS, Claggett BL, et al
    Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial.
    Circulation. 2024 Sep 29. doi: 10.1161/CIRCULATIONAHA.124.072011.
    >> Share

  55. VADUGANATHAN M, Claggett BL, Kulac IJ, Miao ZM, et al
    Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure.
    Circulation. 2024 Sep 28. doi: 10.1161/CIRCULATIONAHA.124.072055.
    >> Share

  56. SHADDY R, Burch M, Kantor PF, Solar-Yohay S, et al
    Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.
    Circulation. 2024 Sep 25. doi: 10.1161/CIRCULATIONAHA.123.066605.
    >> Share

  57. STONE GW, Lindenfeld J, Rodes-Cabau J, Anker SD, et al
    Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial.
    Circulation. 2024 Sep 23. doi: 10.1161/CIRCULATIONAHA.124.070870.
    >> Share

  58. WANG J, Chen B, Shi Q, Ciampa G, et al
    Preventing Site-Specific Calpain Proteolysis of Junctophilin-2 Protects Against Stress-Induced Excitation-Contraction Uncoupling and Heart Failure Development.
    Circulation. 2024 Sep 18. doi: 10.1161/CIRCULATIONAHA.124.069329.
    >> Share


  59. Correction to: Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure.
    Circulation. 2024;150:e268.
    >> Share

  60. TANG WHW, Bakitas MA, Cheng XS, Fang JC, et al
    Evaluation and Management of Kidney Dysfunction in Advanced Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2024 Sep 10. doi: 10.1161/CIR.0000000000001273.
    >> Share

  61. KOSIBOROD MN, Petrie MC, Borlaug BA
    Response by Kosiborod et al to Letter Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial".
    Circulation. 2024;150:e226-e227.
    >> Share

  62. WEIR RAP
    Letter by Weir Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity".
    Circulation. 2024;150:e224-e225.
    >> Share

  63. BUTT JH, McMurray JJ, Claggett BL, Jhund PS, et al
    Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical Trials.
    Circulation. 2024 Sep 1. doi: 10.1161/CIRCULATIONAHA.124.071110.
    >> Share

    August 2024
  64. SOHNS C, Moersdorf M, Marrouche NF, Bergau L, et al
    Catheter Ablation in Patients with End-Stage Heart Failure and Atrial Fibrillation: Two-year Follow-up of the CASTLE-HTx Trial.
    Circulation. 2024 Aug 30. doi: 10.1161/CIRCULATIONAHA.124.071517.
    >> Share

  65. GOPALASINGAM N, Berg-Hansen K, Christensen KH, Ladefoged BT, et al
    Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 Aug 20. doi: 10.1161/CIRCULATIONAHA.124.069732.
    >> Share

  66. CHATUR S, Vaduganathan M, Claggett B, Solomon SD, et al
    Response by Chatur et al to Letter Regarding Article, "Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial".
    Circulation. 2024;150:e107-e108.
    >> Share

  67. WANG J
    Letter by Wang Regarding Article, "Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial".
    Circulation. 2024;150:e106.
    >> Share

  68. GREENE SJ, Butler J, Fonarow GC
    Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: 5 Core Principles.
    Circulation. 2024;150:422-424.
    >> Share

  69. NETUKA I, Tucanova Z, Ivak P, Gregor S, et al
    A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study.
    Circulation. 2024;150:509-511.
    >> Share

  70. TADA A, Burkhoff D, Naser JA, Harada T, et al
    Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial.
    Circulation. 2024 Aug 5. doi: 10.1161/CIRCULATIONAHA.124.068788.
    >> Share

    July 2024
  71. ABOUMSALLEM JP, de Boer RA
    IGFBP7: From Senescence Biomarker to a Vaccine for Heart Failure.
    Circulation. 2024;150:390-392.
    >> Share

  72. YOO SGK, Lam CSP, Sweitzer NK
    "Asian" Heart Failure.
    Circulation. 2024;150:177-179.
    >> Share

  73. WEYRICH M, Cremer S, Gerster M, Sarakpi T, et al
    Loss of Y Chromosome and Cardiovascular Events in Chronic Kidney Disease.
    Circulation. 2024 Jul 15. doi: 10.1161/CIRCULATIONAHA.124.069139.
    >> Share

  74. KATOH M, Nomura S, Yamada S, Ito M, et al
    Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7.
    Circulation. 2024 Jul 11. doi: 10.1161/CIRCULATIONAHA.123.064719.
    >> Share


  75. Correction to: Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target against Ischemic Heart Failure in Prediabetic Animals.
    Circulation. 2024;150:e63.
    >> Share

    June 2024
  76. HOEPER MM, Oerke B, Wissmuller M, Leuchte H, et al
    Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.
    Circulation. 2024 Jun 28. doi: 10.1161/CIRCULATIONAHA.124.069340.
    >> Share

  77. NASER JA, Tada A, Harada T, Reddy YNV, et al
    Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024;149:2026-2028.
    >> Share

  78. DEWAN P, Shen L, Pedro Ferreira J, Jhund PS, et al
    Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF.
    Circulation. 2024 Jun 6. doi: 10.1161/CIRCULATIONAHA.124.068774.
    >> Share

    May 2024
  79. AMDANI S, Conway J, George K, Martinez HR, et al
    Evaluation and Management of Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease: A Scientific Statement From the American Heart Association.
    Circulation. 2024 May 29. doi: 10.1161/CIR.0000000000001245.
    >> Share

  80. JHENG JR, Bai Y, Noda K, Huot JR, et al
    Skeletal Muscle SIRT3 Deficiency Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 May 28. doi: 10.1161/CIRCULATIONAHA.124.068624.
    >> Share

  81. CALLER T, Rotem I, Shaihov-Teper O, Lendengolts D, et al
    Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth.
    Circulation. 2024;149:1729-1748.
    >> Share

  82. PACKER M, Anker SD, Butler J, Cleland JGF, et al
    Redefining Iron Deficiency in Patients With Chronic Heart Failure.
    Circulation. 2024 May 11. doi: 10.1161/CIRCULATIONAHA.124.068883.
    >> Share

  83. SARMA S, Dyck JRB
    Unlocking Pathways That Improve Cardiac Function in Chronic Heart Failure: Are Ketones the Key?
    Circulation. 2024;149:1490-1492.
    >> Share

  84. KANG DH, Park SJ, Shin SH, Hwang IC, et al
    Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial.
    Circulation. 2024 May 1. doi: 10.1161/CIRCULATIONAHA.124.069144.
    >> Share

    April 2024
  85. ZHANG F, Zhang L, Hu G, Chen X, et al
    Rectifying METTL4-Mediated N(6)-Methyladenine Excess in Mitochondrial DNA Alleviates Heart Failure.
    Circulation. 2024 Apr 30. doi: 10.1161/CIRCULATIONAHA.123.068358.
    >> Share

  86. LEMESLE G, Lamblin N, Schurtz G, Labreuche J, et al
    Comparison of Incidence and Prognostic Impact of Ischemic Major Bleeding and Heart Failure Events in Patients With Chronic Coronary Syndrome: Insights From the CORONOR Registry.
    Circulation. 2024 Apr 25. doi: 10.1161/CIRCULATIONAHA.123.067938.
    >> Share

  87. SWAIN L, Bhave S, Qiao X, Reyelt L, et al
    Novel Role for Cardiolipin as a Target of Therapy to Mitigate Myocardial Injury Caused by Venoarterial Extracorporeal Membrane Oxygenation.
    Circulation. 2024;149:1341-1353.
    >> Share


  88. Correction to: Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.
    Circulation. 2024;149:e1130.
    >> Share

  89. LI B, Liu F, Chen X, Chen T, et al
    FARS2 Deficiency Causes Cardiomyopathy by Disrupting Mitochondrial Homeostasis and the Mitochondrial Quality Control System.
    Circulation. 2024;149:1268-1284.
    >> Share

  90. SANDHU AT, Calma J, Skye M, Kalwani NM, et al
    Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic.
    Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069624.
    >> Share

  91. HERNANDEZ AF, Udell JA, Jones WS, Anker SD, et al
    Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial.
    Circulation. 2024 Apr 6. doi: 10.1161/CIRCULATIONAHA.124.069217.
    >> Share

  92. BREATHETT K, Lewsey S, Brownell NK, Enright K, et al
    Implementation Science to Achieve Equity in Heart Failure Care: A Scientific Statement From the American Heart Association.
    Circulation. 2024 Apr 3. doi: 10.1161/CIR.0000000000001231.
    >> Share


  93. Correction to: INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure.
    Circulation. 2024;149:e1066.
    >> Share

  94. GOKULNATH P, Spanos M, Lehmann HI, Sheng Q, et al
    Distinct Plasma Extracellular Vesicle Transcriptomes in Acute Decompensated Heart Failure Subtypes: A Liquid Biopsy Approach.
    Circulation. 2024;149:1147-1149.
    >> Share

  95. KAPELIOS CJ, Lund LH
    Preemptive Versus Urgent Heart Failure Hospitalization as a Surrogate for Mortality Risk in Heart Failure.
    Circulation. 2024;149:1062-1064.
    >> Share

    March 2024
  96. BERG-HANSEN K, Gopalasingam N, Christensen KH, Ladefoged B, et al
    Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial.
    Circulation. 2024 Mar 27. doi: 10.1161/CIRCULATIONAHA.123.067971.
    >> Share

  97. JESSUP M
    A Century of Heart Failure With Reduced Ejection Fraction: Mostly Drought, Followed by Rapid Progress.
    Circulation. 2024;149:899-901.
    >> Share

  98. CLELAND JGF
    Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure.
    Circulation. 2024;149:839-842.
    >> Share

  99. VELIKANOVA D, Poyhonen P, Lehtonen J, Simonen P, et al
    End-Stage Heart Failure in Cardiac Sarcoidosis.
    Circulation. 2024;149:885-887.
    >> Share

    February 2024
  100. HOEDEMAKERS S, Pugliese NR, Stassen J, Vanoppen A, et al
    mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis.
    Circulation. 2024 Feb 27. doi: 10.1161/CIRCULATIONAHA.123.067130.
    >> Share

  101. CRESCI S, Bach RG, Saberi S, Owens AT, et al
    Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
    Circulation. 2024;149:498-509.
    >> Share

  102. GREEN JB, Everett BM, Ghosh A, Younes N, et al
    Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
    Circulation. 2024 Feb 12. doi: 10.1161/CIRCULATIONAHA.123.066604.
    >> Share

  103. JIANG Y, Gu J, Niu X, Hu J, et al
    Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure.
    Circulation. 2024 Feb 8. doi: 10.1161/CIRCULATIONAHA.123.067519.
    >> Share

  104. SANCHEZ RH, Hamdan H, Torrealba J, Grodin JL, et al
    Giants Hiding in Small Places: A Case of New Onset Heart Failure, Atrioventricular Block, and Ventricular Arrhythmias.
    Circulation. 2024;149:475-480.
    >> Share

    January 2024
  105. HERWEG B, Sharma PS, Cano O, Ponnusamy SS, et al
    Arrhythmic Risk in Biventricular Pacing Compared With Left Bundle Branch Area Pacing: Results From the I-CLAS Study.
    Circulation. 2024;149:379-390.
    >> Share

  106. SUMARSONO A, Xie L, Keshvani N, Zhang C, et al
    Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction.
    Circulation. 2024 Jan 23. doi: 10.1161/CIRCULATIONAHA.123.067489.
    >> Share

  107. BROMAN MT, Nadadur RD, Perez-Cervantes C, Burnicka-Turek O, et al
    A Genomic Link From Heart Failure to Atrial Fibrillation Risk: FOG2 Modulates a TBX5/GATA4-Dependent Atrial Gene Regulatory Network.
    Circulation. 2024 Jan 8. doi: 10.1161/CIRCULATIONAHA.123.066804.
    >> Share

    December 2023
  108. REN Z, Zhao W, Li D, Yu P, et al
    INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.065440.
    >> Share

  109. OSTERGAARD L, Olesen JB, Petersen JK, Nielsen LS, et al
    Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA(2)DS(2)-VASc 1: A Nationwide Study.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477.
    >> Share

  110. THOMPSON PD
    Steps May Count for More Than Just Cardiac Risk.
    Circulation. 2023;148:2017-2018.
    >> Share

  111. GOSS KN
    Preterm Birth: An Overlooked Risk Factor for Heart Failure in the Young Adult.
    Circulation. 2023;148:2005-2007.
    >> Share

  112. GOLDENBERG JR, Hays AG, Gabr RE, Sch?r M, et al
    Energetic Basis of Recovered Ejection Fraction in Human Heart Failure.
    Circulation. 2023;148:1976-1978.
    >> Share

  113. VAN DUIJVENBODEN S, Ramirez J, Orini M, Aung N, et al
    Prognostic Significance of Different Ventricular Ectopic Burdens During Submaximal Exercise in Asymptomatic UK Biobank Subjects.
    Circulation. 2023;148:1932-1944.
    >> Share

  114. MCMURRAY JJV, Docherty KF, de Boer RA, Hammarstedt A, et al
    Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
    Circulation. 2023 Dec 7. doi: 10.1161/CIRCULATIONAHA.123.065061.
    >> Share

    November 2023
  115. GREENE SJ, Butler J
    Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics.
    Circulation. 2023;148:1746-1749.
    >> Share

  116. WALKER MA, Chen H, Yadav A, Ritterhoff J, et al
    Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation.
    Circulation. 2023 Nov 15. doi: 10.1161/CIRCULATIONAHA.123.066039.
    >> Share

  117. XU W, Billon C, Li H, Wilderman A, et al
    Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.
    Circulation. 2023 Nov 14. doi: 10.1161/CIRCULATIONAHA.123.066542.
    >> Share

  118. WHELLAN DJ
    Physical Activity for Patients with Heart Failure with Reduced Ejection Fraction: Pump up the Volume.
    Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067588.
    >> Share

  119. VETROVSKY T, Siranec M, Frybova T, Gant I, et al
    Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial.
    Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067395.
    >> Share

  120. KOSIBOROD MN, Verma S, Borlaug BA, Butler J, et al
    Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
    Circulation. 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.067505.
    >> Share

  121. PATEL KV, Segar MW, Klonoff DC, Khan MS, et al
    Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis.
    Circulation. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067530.
    >> Share

  122. KHAN SS, Coresh J, Pencina MJ, Ndumele CE, et al
    Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association.
    Circulation. 2023 Nov 10. doi: 10.1161/CIR.0000000000001191.
    >> Share

  123. KHAN SS, Matsushita K, Sang Y, Ballew SH, et al
    Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations.
    Circulation. 2023 Nov 10. doi: 10.1161/CIRCULATIONAHA.123.067626.
    >> Share

  124. BAWASKAR P, Thomas N, Ismail KF, Guo Y, et al
    Non-ischemic or Dual Cardiomyopathy in Patients with Coronary Artery Disease.
    Circulation. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.067032.
    >> Share

    October 2023
  125. ZAMANI SK, Sarma S, MacNamara JP, Hynan LS, et al
    Excess Pericardial Fat Is Related to Adverse Cardio-Mechanical Interaction in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023;148:1410-1412.
    >> Share

  126. WAKEHAM DJ, Ivey E, Saland S, Lewis J, et al
    Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.
    Circulation. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.066170.
    >> Share

  127. OSTROMINSKI JW, Vaduganathan M, Selvaraj S, Claggett BL, et al
    Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.
    Circulation. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.065254.
    >> Share

  128. BUTT JH, Yafasova A, Doi SN, Nielsen JC, et al
    Implantable Cardioverter Defibrillator in Patients With Nonischemic Systolic Heart Failure With and Without Cardiac Resynchronization Therapy: Extended Follow-Up Study of the DANISH Trial.
    Circulation. 2023;148:1179-1181.
    >> Share

    September 2023
  129. GODFREY S, Kirkpatrick JN, Kramer DB, Sulistio MS, et al
    Expanding the Paradigm for Cardiovascular Palliative Care.
    Circulation. 2023;148:1039-1052.
    >> Share

  130. PARKASH R, O'Meara E, Tang ASL
    The Role of Ablation-Based Rhythm Control in the Tangled Web of Atrial Fibrillation and Heart Failure.
    Circulation. 2023;148:933-935.
    >> Share

  131. LEBEK S, Caravia XM, Chemello F, Tan W, et al
    Elimination of CaMKIIdelta Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice.
    Circulation. 2023 Sep 15. doi: 10.1161/CIRCULATIONAHA.123.065117.
    >> Share

  132. COCHRAN J, Yura Y, Thel MC, Doviak H, et al
    Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023 Sep 8. doi: 10.1161/CIRCULATIONAHA.123.064170.
    >> Share

  133. CHEW DS, Li Y, Bigelow R, Cowper PA, et al
    Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
    Circulation. 2023 Sep 6. doi: 10.1161/CIRCULATIONAHA.122.063602.
    >> Share

  134. ZHU H, Song YC, Hang PZ
    Letter by Zhu et al Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure".
    Circulation. 2023;148:855-856.
    >> Share

  135. ARONSEN JM, Skogestad J, Albert I, Melleby AO, et al
    Response by Aronsen et al to Letter Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure".
    Circulation. 2023;148:857-858.
    >> Share

    August 2023
  136. HEIDENREICH P
    What Is a Normal Left Ventricular Ejection Fraction?
    Circulation. 2023;148:750-752.
    >> Share

  137. CHATUR S, Vaduganathan M, Claggett BL, Cunningham JW, et al
    Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
    Circulation. 2023 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.066506.
    >> Share

  138. PACKER M, Butler J, Zeller C, Pocock SJ, et al
    Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
    Circulation. 2023 Aug 24. doi: 10.1161/CIRCULATIONAHA.123.065748.
    >> Share


  139. Correction to: Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?
    Circulation. 2023;148:e7.
    >> Share

  140. SARMA S, Levine BD
    Response by Sarma and Levine to Letters Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
    Circulation. 2023;148:620-621.
    >> Share

  141. WUSSLER D, Belkin M, Mueller C
    Letter by Wussler et al Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
    Circulation. 2023;148:619.
    >> Share

  142. RAGONE I, Barallobre-Barreiro J, Takov K, Theofilatos K, et al
    SERCA2a Protein Levels Are Unaltered in Human Heart Failure.
    Circulation. 2023;148:613-616.
    >> Share

  143. DIMOPOULOS S, Nanas S
    Letter by Dimopoulos and Nanas Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
    Circulation. 2023;148:617-618.
    >> Share

  144. BORLAUG BA, Reddy YNV, Braun A, Sorimachi H, et al
    Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
    Circulation. 2023 Aug 3. doi: 10.1161/CIRCULATIONAHA.123.065134.
    >> Share

    July 2023
  145. PACKER M, Wilcox CS, Testani JM
    Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
    Circulation. 2023;148:354-372.
    >> Share

  146. MENTIAS A, Mujahid MS, Sumarsono A, Nelson RK, et al
    Historical Redlining, Socioeconomic Distress, and Risk of Heart Failure Among Medicare Beneficiaries.
    Circulation. 2023;148:210-219.
    >> Share

  147. WATSON WD, Green PG, Lewis AJM, Arvidsson P, et al
    Retained Metabolic Flexibility of the Failing Human Heart.
    Circulation. 2023;148:109-123.
    >> Share

  148. GHADIMI K, Cappiello JL, Wright MC, Levy JH, et al
    Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.
    Circulation. 2023 Jul 4. doi: 10.1161/CIRCULATIONAHA.122.062464.
    >> Share

    June 2023
  149. KONDO T, Dewan P, Anand IS, Desai AS, et al
    Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
    Circulation. 2023 Jun 27. doi: 10.1161/CIRCULATIONAHA.122.063642.
    >> Share

  150. HITSUMOTO T, Tsukamoto O, Matsuoka K, Li J, et al
    Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin.
    Circulation. 2023;147:1902-1918.
    >> Share

    May 2023
  151. TANG Y, Feng M, Su Y, Ma T, et al
    Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy.
    Circulation. 2023;147:1684-1704.
    >> Share

  152. GREENE SJ, Velazquez EJ, Anstrom KJ, Clare RM, et al
    Effect of Torsemide vs Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
    Circulation. 2023 May 22. doi: 10.1161/CIRCULATIONAHA.123.064842.
    >> Share

  153. JANI V, Aslam MI, Fenwick AJ, Ma W, et al
    Right Ventricular Sarcomere Contractile Depression and the Role of Thick Filament Activation in Human Heart Failure With Pulmonary Hypertension.
    Circulation. 2023 May 17. doi: 10.1161/CIRCULATIONAHA.123.064717.
    >> Share

  154. GUPTA K, Spertus JA, Birmingham M, Gosch KL, et al
    Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.
    Circulation. 2023 May 16. doi: 10.1161/CIRCULATIONAHA.122.063263.
    >> Share

  155. SATTAR N, McMurray J, Boren J, Rawshani A, et al
    Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study.
    Circulation. 2023 May 8. doi: 10.1161/CIRCULATIONAHA.122.063374.
    >> Share

    April 2023
  156. HUNDERTMARK MJ, Adler A, Antoniades C, Coleman R, et al
    Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
    Circulation. 2023 Apr 18. doi: 10.1161/CIRCULATIONAHA.122.062021.
    >> Share

  157. BUTLER J, Talha KM, Fonarow GC
    STRONG-HF and Implementing Heart Failure Therapies: Godspeed ... With Care.
    Circulation. 2023;147:1189-1191.
    >> Share

  158. FILIPPATOS G, Ponikowski P, Farmakis D, Anker SD, et al
    Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
    Circulation. 2023 Apr 13. doi: 10.1161/CIRCULATIONAHA.122.060757.
    >> Share

  159. ERN YEOH S, Docherty KF, Campbell RT, Jhund PS, et al
    Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
    Circulation. 2023 Apr 11. doi: 10.1161/CIRCULATIONAHA.122.063327.
    >> Share

  160. MENTIAS A, Peterson ED, Keshvani N, Kumbhani DJ, et al
    Achieving Equity in Hospital Performance Assessments Using Composite Race-Specific Measures of Risk-Standardized Readmission and Mortality Rates for Heart Failure.
    Circulation. 2023;147:1121-1133.
    >> Share


  161. Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2023;147:e674.
    >> Share

  162. BUTT JH, Solomon SD, McMurray JJV
    Response by Butt et al to Letter Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
    Circulation. 2023;147:1119-1120.
    >> Share

  163. WONG EKC, Demers C
    Letter by Wong and Demers Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
    Circulation. 2023;147:1118.
    >> Share

    March 2023
  164. SACHDEV V, Sharma K, Keteyian SJ, Alcain CF, et al
    Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Circulation. 2023 Mar 21. doi: 10.1161/CIR.0000000000001122.
    >> Share

  165. SELVARAJ S, Kosiborod MN, Shah SH
    Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
    Circulation. 2023;147:922-923.
    >> Share

  166. TACHIBANA S, Yu NK, Li R, Fernandez-Costa C, et al
    Perm1 Protects the Heart From Pressure Overload-Induced Dysfunction by Promoting Oxidative Metabolism.
    Circulation. 2023;147:916-919.
    >> Share

  167. MONZO L, Melenovsky V
    Letter by Monzo and Melenovsky Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
    Circulation. 2023;147:920-921.
    >> Share

  168. MENG Z, Zhang Z, Zhao J, Liu C, et al
    Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target Against Ischemic Heart Failure in Prediabetic Animals.
    Circulation. 2023 Mar 8. doi: 10.1161/CIRCULATIONAHA.122.063073.
    >> Share

  169. KUEHN BM
    Collaborative Care Model Helps Patients With Heart Failure Meet End-of-Life Goals.
    Circulation. 2023;147:841-842.
    >> Share

  170. FRIEDMAN DJ, Al-Khatib SM, Dalgaard F, Fudim M, et al
    Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials.
    Circulation. 2023;147:812-823.
    >> Share

  171. SKOGESTAD J, Albert I, Hougen K, Lothe GB, et al
    Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure.
    Circulation. 2023 Mar 6. doi: 10.1161/CIRCULATIONAHA.121.054168.
    >> Share

  172. KONDO T, Jering KS, Borleffs CJW, de Boer RA, et al
    Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial.
    Circulation. 2023 Mar 6. doi: 10.1161/CIRCULATIONAHA.122.062918.
    >> Share

  173. HAHN VS, Petucci C, Kim MS, Bedi KC Jr, et al
    Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023 Mar 1. doi: 10.1161/CIRCULATIONAHA.122.061846.
    >> Share

    February 2023
  174. LEYVA F, Israel CW, Singh J
    Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?
    Circulation. 2023;147:759-767.
    >> Share

    December 2022
  175. SHELBAYA K, Claggett B, Dorbala P, Skali H, et al
    Stages of Valvular Heart Disease Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study.
    Circulation. 2022 Dec 16. doi: 10.1161/CIRCULATIONAHA.122.061396.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016